These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1316175)

  • 41. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
    Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
    Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
    Zwelling LA; Mayes J; Hinds M; Chan D; Altschuler E; Carroll B; Parker E; Deisseroth K; Radcliffe A; Seligman M
    Biochemistry; 1991 Apr; 30(16):4048-55. PubMed ID: 1850298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
    Nitiss JL; Liu YX; Hsiung Y
    Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.
    Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC
    Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
    Nitiss JL; Vilalta PM; Wu H; McMahon J
    Mol Pharmacol; 1994 Oct; 46(4):773-7. PubMed ID: 7969059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A drug-resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub-nuclear distribution.
    Boege F; Kjeldsen E; Gieseler F; Alsner J; Biersack H
    Eur J Biochem; 1993 Dec; 218(2):575-84. PubMed ID: 8269948
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities toward monocytoid differentiation.
    Zwelling LA; Hinds M; Chan D; Altschuler E; Mayes J; Zipf TF
    Cancer Res; 1990 Nov; 50(22):7116-22. PubMed ID: 2171756
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells.
    Sullivan DM; Latham MD; Ross WE
    Cancer Res; 1987 Aug; 47(15):3973-9. PubMed ID: 3038304
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
    Bakic M; Chan D; Andersson BS; Beran M; Silberman L; Estey E; Ricketts L; Zwelling LA
    Biochem Pharmacol; 1987 Dec; 36(23):4067-77. PubMed ID: 2825713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug-sensitivity and DNA-binding of a subform of topoisomerase II alpha in resistant human HL-60 cells.
    Boege F; Biersack H; Meyer P
    Acta Oncol; 1994; 33(7):799-806. PubMed ID: 7993649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of anion-exchange chromatography and chromatofocusing to reveal the structural and functional heterogeneity of topoisomerase II in a HL-60 cell line resistant to multi-drug treatment.
    Boege F; Gieseler F; Biersack H; Clark M
    J Chromatogr; 1991 Nov; 587(1):3-9. PubMed ID: 1664428
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target.
    Mayes J; Hinds M; Soares L; Altschuler E; Kim P; Zwelling LA
    Biochem Pharmacol; 1993 Aug; 46(4):699-707. PubMed ID: 8395843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.
    Harker WG; Slade DL; Drake FH; Parr RL
    Biochemistry; 1991 Oct; 30(41):9953-61. PubMed ID: 1655025
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Different functional states of topoisomerase II can be discriminated by orthovanadate sensitivity in multi-drug resistant human leukemic cells.
    Boege F; Gieseler F; Biersack H; Meyer P
    Leuk Lymphoma; 1993 Mar; 9(4-5):381-3. PubMed ID: 8394170
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.
    Fernandes DJ; Danks MK; Beck WT
    Biochemistry; 1990 May; 29(17):4235-41. PubMed ID: 2163274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
    Finlay GJ; Riou JF; Baguley BC
    Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.
    Danks MK; Schmidt CA; Cirtain MC; Suttle DP; Beck WT
    Biochemistry; 1988 Nov; 27(24):8861-9. PubMed ID: 2853972
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Microsomal activation and increased production of 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide (m-AMSA)-dependent, topoisomerase-associated DNA lesions in nuclei from human HL-60 leukemia cells.
    Gorsky LD; Morin MJ
    Biochem Pharmacol; 1990 May; 39(9):1481-4. PubMed ID: 2159306
    [No Abstract]   [Full Text] [Related]  

  • 59. Correlation between the DNA-binding affinity of topoisomerase inhibiting drugs and their capacity to induce hematopoetic cell differentiation.
    Gieseler F; Boege F; Clark M; Meyer P
    Toxicol Lett; 1993 Apr; 67(1-3):331-40. PubMed ID: 8383890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.
    Finlay GJ; Marshall E; Matthews JH; Paull KD; Baguley BC
    Cancer Chemother Pharmacol; 1993; 31(5):401-6. PubMed ID: 8381721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.